Business Wire Industry News

Friday, April 3, 2020

Covalon Announces Conference Call to Discuss New CovaGuard Antimicrobial Technology

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- #antimicrobial--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces a conference call to further discuss its new CovaGuard antimicrobial technology. “We have received a positive response regarding our announcement about the new CovaGuard antimicrobial technology,” said Brian Pedlar, President and Chief Executive Officer. “With the many business opportunities and queries about the technology

Thursday, April 2, 2020

Avivagen Inc. to Issue Shares to Holders of Debentures in Lieu of Annual Maintenance Fee

OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that a total of 3,752 common shares will be issued at the rate of $0.61 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019. Such shares will be issued with effect as of April 9, 2020. This issuance is further to Avivagen’s previous announcement that it had opted to issue common shares to satisfy $107,560 owing to the holders of 10% sec

Thursday, April 2, 2020

Acerus Provides Business Update Related to the Impact of COVID-19

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic. “We are in unprecedented times as we deal with the impact of the ongoing COVID-19 pandemic”, said Ed Gudaitis, President and CEO, Acerus Pharmaceuticals. “Our highest priority is to ensure the safety of our employees and our healthcare professional partners, while ensuring the st

Wednesday, April 1, 2020

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibo

Wednesday, April 1, 2020

Bioasis Announces Shares for Debt Transaction

GUILFORD, Conn.--(BUSINESS WIRE)--Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to satisfy its obligation to pay $28,076.55

Tuesday, March 31, 2020

Covalon Clarifies Previous Press Release

MISSISSAUGA, Ontario--(BUSINESS WIRE)--At the request of IIROC, Investment Industry Regulatory Organization of Canada, Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has been asked to clarify the press release issued earlier today. At IIROC’s request, the Company retracts the title to its last press release because IIROC has deemed the title overly promotional. At IIROC’s request, the Company modifies the title to “Cov

Tuesday, March 31, 2020

Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease

MONTREAL--(BUSINESS WIRE)--Mimetogen Pharmaceuticals Inc. (“Mimetogen”), a clinical-stage biopharmaceutical company focused on the development of tavilermide, a first-in-class nerve growth factor (NGF) mimetic for the treatment of dry eye disease, today announced that it completed enrollment of its 600-patient MIM-728 Phase 3 clinical trial for tavilermide ophthalmic solution. The MIM-728 trial is a multicenter, randomized, double-masked, placebo-controlled, parallel-group study comparing the e

Tuesday, March 31, 2020

VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine Candidate Targeting COVID-19, SARS, and MERS

CAMBRIDGE, Mass. & OTTAWA, Ontario--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respirato

Tuesday, March 31, 2020

 Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- #advancedmedical--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces today its new breakthrough antimicrobial technology formulated to kill the COVID-19 virus (or “SARS-CoV-2”) and other viruses, bacteria, and pathogens. The new technology, called CovaGuard™, has been specifically formulated to be effective at killing pathogens like the COVID-19 virus on contact with the added benefit of prov

Monday, March 30, 2020

Columbia Care Receives Approval to Trade on the Canadian Securities Exchange (CSE)

NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) announced today that it has received approval for the dual listing of its common shares on the Canadian Securities Exchange (CSE). Columbia Care’s common shares will begin trading in Canadian Dollars on the CSE on March 31, 2020 under the symbol CCHW. In addition, the Company’s common shares will continue to trade in Canadian Dollars on its primary, senior listing exchange, the

Monday, March 30, 2020

IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical operations amid the COVID-19 pandemic. “As the COVID-19 pandemic continues to spread, we have taken all necessary measures to prioritize the health and safety of our employees, patients, investigators